Graphite Bio, Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly co…
Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Graphite Bio, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDGraphite Bio, Inc. can't present revenue by segment